{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T06:08:02Z","timestamp":1782367682434,"version":"3.54.5"},"reference-count":127,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T00:00:00Z","timestamp":1634688000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological Sciences"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.jphs.2021.10.010","type":"journal-article","created":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T21:12:41Z","timestamp":1635801161000},"page":"142-151","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Quantitative prediction of pharmacokinetic properties of drugs in humans: Recent advance in in\u00a0vitro models to predict the impact of efflux transporters in the small intestine and blood\u2013brain barrier"],"prefix":"10.1016","volume":"148","author":[{"given":"Yoshiki","family":"Hashimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyoshi","family":"Michiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Kusuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jphs.2021.10.010_bib1","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0169-409X(02)00013-3","article-title":"Physiologically-based pharmacokinetic simulation modelling","volume":"54","author":"Grass","year":"2002","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.jphs.2021.10.010_bib2","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/0006-291X(91)91647-U","article-title":"Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells","volume":"175","author":"Artursson","year":"1991","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jphs.2021.10.010_bib3","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1124\/dmd.110.034629","article-title":"Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model","volume":"39","author":"Lin","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jphs.2021.10.010_bib4","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1208\/s12248-013-9456-8","article-title":"Drug discovery and regulatory considerations for improving in silico and in\u00a0vitro predictions that use Caco-2 as a surrogate for human intestinal permeability measurements","volume":"15","author":"Larregieu","year":"2013","journal-title":"AAPS J"},{"key":"10.1016\/j.jphs.2021.10.010_bib5","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ejps.2008.08.004","article-title":"Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories","volume":"35","author":"Hayeshi","year":"2008","journal-title":"Eur J Pharmaceut Sci"},{"key":"10.1016\/j.jphs.2021.10.010_bib6","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1124\/dmd.120.000138","article-title":"Characterization of the human intestinal drug transport with using chamber system incorporating freshly isolated human jejunum","volume":"49","author":"Michiba","year":"2021","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jphs.2021.10.010_bib7","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1124\/dmd.116.074377","article-title":"Human enterocytes as an In\u00a0vitro model for the evaluation of intestinal drug metabolism: characterization of drug-metabolizing enzyme activities of cryopreserved human enterocytes from twenty-four donors","volume":"45","author":"Ho","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jphs.2021.10.010_bib8","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.stemcr.2020.12.017","article-title":"Generation of human-induced pluripotent stem cell-derived functional enterocyte-like cells for pharmacokinetic studies","volume":"16","author":"Yoshida","year":"2021","journal-title":"Stem Cell Rep"},{"key":"10.1016\/j.jphs.2021.10.010_bib9","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1124\/dmd.114.062604","article-title":"Generation of enterocyte-like cells with pharmacokinetic functions from human induced pluripotent stem cells using small-molecule compounds","volume":"43","author":"Iwao","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jphs.2021.10.010_bib10","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.dmpk.2016.02.002","article-title":"Inhibition of mitogen-activated protein kinase, DNA methyltransferase, and transforming growth factor-beta promotes differentiation of human induced pluripotent stem cells into enterocytes","volume":"31","author":"Kodama","year":"2016","journal-title":"Drug Metabol Pharmacokinet"},{"key":"10.1016\/j.jphs.2021.10.010_bib11","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1124\/dmd.118.082123","article-title":"Cyclic AMP signaling promotes the differentiation of human induced pluripotent stem cells into intestinal epithelial cells","volume":"46","author":"Kabeya","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jphs.2021.10.010_bib12","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.dmpk.2020.04.334","article-title":"Pharmacokinetic functions of human induced pluripotent stem cell-derived small intestinal epithelial cells","volume":"35","author":"Kabeya","year":"2020","journal-title":"Drug Metabol Pharmacokinet"},{"key":"10.1016\/j.jphs.2021.10.010_bib13","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.dmpk.2020.01.009","article-title":"Establishment of MDR1-knockout human induced pluripotent stem cell line","volume":"35","author":"Negoro","year":"2020","journal-title":"Drug Metabol Pharmacokinet"},{"key":"10.1016\/j.jphs.2021.10.010_bib14","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nature07935","article-title":"Single Lgr5 stem cells build crypt-villus structures in\u00a0vitro without a mesenchymal niche","volume":"459","author":"Sato","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.jphs.2021.10.010_bib15","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1053\/j.gastro.2011.07.050","article-title":"Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium","volume":"141","author":"Sato","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jphs.2021.10.010_bib16","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nature09691","article-title":"Directed differentiation of human pluripotent stem cells into intestinal tissue in\u00a0vitro","volume":"470","author":"Spence","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.jphs.2021.10.010_bib17","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1038\/nprot.2011.410","article-title":"Generating human intestinal tissue from pluripotent stem cells in\u00a0vitro","volume":"6","author":"McCracken","year":"2011","journal-title":"Nat Protoc"},{"key":"10.1016\/j.jphs.2021.10.010_bib18","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1124\/dmd.118.080374","article-title":"Generation of intestinal organoids suitable for pharmacokinetic studies from human induced pluripotent stem cells","volume":"46","author":"Onozato","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jphs.2021.10.010_bib19","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1124\/dmd.118.083246","article-title":"Application of intestinal epithelial cells differentiated from human induced pluripotent stem cells for studies of prodrug hydrolysis and drug absorption in the small intestine","volume":"46","author":"Akazawa","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jphs.2021.10.010_bib20","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1089\/ten.tec.2016.0101","article-title":"Development of an advanced primary human In\u00a0vitro model of the small intestine","volume":"22","author":"Schweinlin","year":"2016","journal-title":"Tissue Eng C Methods"},{"key":"10.1016\/j.jphs.2021.10.010_bib21","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/stem.1655","article-title":"Adult stem cells in the small intestine are intrinsically programmed with their location-specific function","volume":"32","author":"Middendorp","year":"2014","journal-title":"Stem Cell"},{"key":"10.1016\/j.jphs.2021.10.010_bib22","first-page":"698","article-title":"WRN conditioned media is sufficient for in\u00a0vitro propagation of intestinal organoids from large farm and small companion animals","volume":"6","author":"Powell","year":"2017","journal-title":"Biol Open"},{"key":"10.1016\/j.jphs.2021.10.010_bib23","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/clpt.2008.195","article-title":"Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in\u00a0vitro-in\u00a0vivo correlation using digoxin as a probe drug","volume":"85","author":"Fenner","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jphs.2021.10.010_bib24","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1046\/j.1365-2125.2003.01824.x","article-title":"Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction","volume":"56","author":"Rengelshausen","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jphs.2021.10.010_bib25","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/sj.clpt.6100452","article-title":"Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients","volume":"84","author":"Wyen","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jphs.2021.10.010_bib26","doi-asserted-by":"crossref","first-page":"192","DOI":"10.5414\/CPP48192","article-title":"Effect of saquinavir\/ritonavir on P-glycoprotein activity in healthy volunteers using digoxin as a probe","volume":"48","author":"Schmitt","year":"2010","journal-title":"Int J Clin Pharmacol Therapeut"},{"key":"10.1016\/j.jphs.2021.10.010_bib27","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1177\/0091270011419850","article-title":"Effect of telaprevir on the pharmacokinetics of midazolam and digoxin","volume":"52","author":"Garg","year":"2012","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.jphs.2021.10.010_bib28","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/cpdd.189","article-title":"Effect of lapatinib on oral digoxin absorption in patients","volume":"4","author":"Koch","year":"2015","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.jphs.2021.10.010_bib29","unstructured":"EMBASE: 1994100931."},{"key":"10.1016\/j.jphs.2021.10.010_bib30","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0149-2918(01)80049-7","article-title":"Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study","volume":"23","author":"Gupta","year":"2001","journal-title":"Clin Therapeut"},{"key":"10.1016\/j.jphs.2021.10.010_bib31","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1124\/dmd.105.004622","article-title":"Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans","volume":"33","author":"Shimizu","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jphs.2021.10.010_bib32","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1124\/dmd.105.008375","article-title":"Inhibition of oat3-mediated renal uptake as a mechanism for drug-drug interaction between fexofenadine and probenecid","volume":"34","author":"Tahara","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jphs.2021.10.010_bib33","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1124\/dmd.107.017814","article-title":"Investigation of the inhibitory effects of various drugs on the hepatic uptake of fexofenadine in humans","volume":"36","author":"Matsushima","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jphs.2021.10.010_bib34","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1172\/JCI6663","article-title":"The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin","volume":"104","author":"Greiner","year":"1999","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jphs.2021.10.010_bib35","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/mc.2940130302","article-title":"Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy","volume":"13","author":"Wacher","year":"1995","journal-title":"Mol Carcinog"},{"key":"10.1016\/j.jphs.2021.10.010_bib36","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1046\/j.1365-2125.1998.t01-1-00687.x","article-title":"Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man","volume":"45","author":"Kupferschmidt","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jphs.2021.10.010_bib37","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0009-9236(98)90041-8","article-title":"Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir","volume":"63","author":"Hsu","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jphs.2021.10.010_bib38","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/jcph.62","article-title":"Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; micro\/small dosing tests using midazolam (CYP3A4), fexofenadine (p-glycoprotein), and pravastatin (OATP1B1) as probe drugs","volume":"53","author":"Ieiri","year":"2013","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.jphs.2021.10.010_bib39","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1073\/pnas.97.7.3473","article-title":"Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in\u00a0vivo","volume":"97","author":"Hoffmeyer","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jphs.2021.10.010_bib40","first-page":"68","article-title":"A\u00a0global reference for human genetic variation, the 1000 Genomes Project Consortium","volume":"526","author":"Auton","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jphs.2021.10.010_bib41","first-page":"107","article-title":"Impact of ABCB1 (MDR1) gene polymorphism and P-glycoprotein inhibitors on digoxin serum concentration in congestive heart failure patients","volume":"59","author":"Kurzawski","year":"2007","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.jphs.2021.10.010_bib42","doi-asserted-by":"crossref","first-page":"650","DOI":"10.4161\/cbt.4.6.1731","article-title":"Effect of ABCG2 genotype on the oral bioavailability of topotecan","volume":"4","author":"Sparreboom","year":"2005","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.jphs.2021.10.010_bib43","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/sj.clpt.6100459","article-title":"Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans","volume":"84","author":"Yamasaki","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jphs.2021.10.010_bib44","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/clpt.2009.79","article-title":"ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin","volume":"86","author":"Keskitalo","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jphs.2021.10.010_bib45","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1124\/dmd.104.001628","article-title":"Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta","volume":"33","author":"Kobayashi","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jphs.2021.10.010_bib46","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1023\/B:PHAM.0000045245.21637.d4","article-title":"Functional analysis of SNPs variants of BCRP\/ABCG2","volume":"21","author":"Kondo","year":"2004","journal-title":"Pharm Res (N Y)"},{"key":"10.1016\/j.jphs.2021.10.010_bib47","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/ijc.11669","article-title":"Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2","volume":"109","author":"Mizuarai","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jphs.2021.10.010_bib48","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1111\/j.1476-5381.2012.01887.x","article-title":"Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in\u00a0vivo inhibitor of BCRP","volume":"166","author":"Kusuhara","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jphs.2021.10.010_bib49","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.2217\/pgs.09.85","article-title":"Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin","volume":"10","author":"Keskitalo","year":"2009","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jphs.2021.10.010_bib50","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/S0022-3565(24)29609-9","article-title":"Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes","volume":"297","author":"Nakai","year":"2001","journal-title":"J\u00a0Pharmacol Exp Therapeut"},{"key":"10.1016\/j.jphs.2021.10.010_bib51","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S0009-9236(03)00060-2","article-title":"Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics","volume":"73","author":"Nishizato","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jphs.2021.10.010_bib52","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/sj.clpt.6100190","article-title":"SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers","volume":"82","author":"Ieiri","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jphs.2021.10.010_bib53","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/cpt.749","article-title":"Endogenous probes for drug transporters: balancing vision with reality","volume":"103","author":"Rodrigues","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jphs.2021.10.010_bib54","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1002\/cpt.1216","article-title":"Clinical probes and endogenous biomarkers as substrates for transporter drug-drug interaction evaluation: perspectives from the international transporter consortium","volume":"104","author":"Chu","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jphs.2021.10.010_bib55","doi-asserted-by":"crossref","first-page":"100358","DOI":"10.1016\/j.dmpk.2020.09.003","article-title":"Current progress in identifying endogenous biomarker candidates for drug transporter phenotyping and their potential application to drug development","volume":"37","author":"Mochizuki","year":"2021","journal-title":"Drug Metabol Pharmacokinet"},{"key":"10.1016\/j.jphs.2021.10.010_bib56","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.dmpk.2018.09.003","article-title":"Effect of OATP1B1 genotypes on plasma concentrations of endogenous OATP1B1 substrates and drugs, and their association in healthy volunteers","volume":"34","author":"Mori","year":"2019","journal-title":"Drug Metabol Pharmacokinet"},{"key":"10.1016\/j.jphs.2021.10.010_bib57","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/cts.12889","article-title":"Substantially increased plasma coproporphyrin-I concentrations associated with OATP1B1\u221715 allele in Japanese general population","volume":"14","author":"Suzuki","year":"2021","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jphs.2021.10.010_bib58","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s11095-018-2416-3","article-title":"Comparative study of the dose-dependence of OATP1B inhibition by rifampicin using probe drugs and endogenous substrates in healthy volunteers","volume":"35","author":"Takehara","year":"2018","journal-title":"Pharm Res (N Y)"},{"key":"10.1016\/j.jphs.2021.10.010_bib59","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1002\/cpt.1695","article-title":"Dose-dependent inhibition of OATP1B by rifampicin in healthy volunteers: comprehensive evaluation of candidate biomarkers and OATP1B probe drugs","volume":"107","author":"Mori","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jphs.2021.10.010_bib60","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/cts.12888","article-title":"Coproporphyrin I can serve as an endogenous biomarker for OATP1B1 inhibition: assessment using a glecaprevir\/pibrentasvir clinical study","volume":"14","author":"Kalluri","year":"2021","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jphs.2021.10.010_bib61","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/cpt.1599","article-title":"Complex DDI by fenebrutinib and the use of transporter endogenous biomarkers to elucidate the mechanism of DDI","volume":"107","author":"Jones","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jphs.2021.10.010_bib62","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1080\/00498250902846252","article-title":"Method for predicting the risk of drug-drug interactions involving inhibition of intestinal CYP3A4 and P-glycoprotein","volume":"39","author":"Tachibana","year":"2009","journal-title":"Xenobiotica"},{"key":"10.1016\/j.jphs.2021.10.010_bib63","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/jps.21114","article-title":"Effect of P-glycoprotein expression levels on the concentration-dependent permeability of drugs to the cell membrane","volume":"97","author":"Shirasaka","year":"2008","journal-title":"J\u00a0Pharmacol Sci"},{"key":"10.1016\/j.jphs.2021.10.010_bib64","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s11095-009-0026-9","article-title":"Model analysis of the concentration-dependent permeability of P-gp substrates","volume":"27","author":"Tachibana","year":"2010","journal-title":"Pharm Res (N Y)"},{"key":"10.1016\/j.jphs.2021.10.010_bib65","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1124\/dmd.116.070011","article-title":"The prediction of the relative importance of CYP3A\/P-glycoprotein to the nonlinear intestinal absorption of drugs by advanced compartmental absorption and transit model","volume":"44","author":"Takano","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jphs.2021.10.010_bib66","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/jlcr.2993","article-title":"Radioligands targeting P-glycoprotein and other drug efflux proteins at the blood-brain barrier","volume":"56","author":"Wanek","year":"2013","journal-title":"J\u00a0Label Compd Radiopharm"},{"key":"10.1016\/j.jphs.2021.10.010_bib67","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1586\/14789450.2014.893830","article-title":"Quantitative targeted proteomics for understanding the blood-brain barrier: towards pharmacoproteomics","volume":"11","author":"Ohtsuki","year":"2014","journal-title":"Expert Rev Proteomics"},{"key":"10.1016\/j.jphs.2021.10.010_bib68","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.2174\/0929867325666180327092639","article-title":"ABC transporters in extrahepatic tissues: pharmacological regulation in heart and intestine","volume":"26","author":"Villanueva","year":"2019","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.jphs.2021.10.010_bib69","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2133\/dmpk.DMPK-14-RG-026","article-title":"Utility of cerebrospinal fluid drug concentration as a surrogate for unbound brain concentration in nonhuman primates","volume":"29","author":"Nagaya","year":"2014","journal-title":"Drug Metabol Pharmacokinet"},{"key":"10.1016\/j.jphs.2021.10.010_bib70","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1124\/dmd.120.000099","article-title":"Impact of P-Glycoprotein-Mediated active efflux on drug distribution into lumbar cerebrospinal fluid in nonhuman primates","volume":"48","author":"Nagaya","year":"2020","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jphs.2021.10.010_bib71","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1021\/acs.molpharmaceut.7b00449","article-title":"Quantification of transporter and receptor proteins in dog brain capillaries and choroid plexus: relevance for the distribution in brain and CSF of selected BCRP and P-gp substrates","volume":"14","author":"Braun","year":"2017","journal-title":"Mol Pharm"},{"key":"10.1016\/j.jphs.2021.10.010_bib72","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.clpt.2005.01.022","article-title":"Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography","volume":"77","author":"Sasongko","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jphs.2021.10.010_bib73","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/clpt.2010.11","article-title":"Regional P-glycoprotein activity and inhibition at the human blood-brain barrier as imaged by positron emission tomography","volume":"87","author":"Eyal","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jphs.2021.10.010_bib74","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1124\/jpet.105.088328","article-title":"In\u00a0vivo evaluation of P-glycoprotein function at the blood-brain barrier in nonhuman primates using [11C]verapamil","volume":"316","author":"Lee","year":"2006","journal-title":"J\u00a0Pharmacol Exp Therapeut"},{"key":"10.1016\/j.jphs.2021.10.010_bib75","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1124\/dmd.107.018176","article-title":"In\u00a0vitro-to-in\u00a0vivo prediction of P-glycoprotein-based drug interactions at the human and rodent blood-brain barrier","volume":"36","author":"Hsiao","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jphs.2021.10.010_bib76","first-page":"1531","article-title":"Quantitative analysis of 11C-verapamil transfer at the human blood-brain barrier for evaluation of P-glycoprotein function","volume":"47","author":"Ikoma","year":"2006","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.jphs.2021.10.010_bib77","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.dmpk.2016.11.007","article-title":"Quantitative prediction of histamine H1 receptor occupancy by the sedative and non-sedative antagonists in the human central nervous system based on systemic exposure and preclinical data","volume":"32","author":"Kanamitsu","year":"2017","journal-title":"Drug Metabol Pharmacokinet"},{"key":"10.1016\/j.jphs.2021.10.010_bib78","doi-asserted-by":"crossref","first-page":"950","DOI":"10.2967\/jnumed.110.083949","article-title":"Developmental changes in P-glycoprotein function in the blood-brain barrier of nonhuman primates: PET study with R-11C-verapamil and 11C-oseltamivir","volume":"52","author":"Takashima","year":"2011","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.jphs.2021.10.010_bib79","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1111\/bcp.13301","article-title":"Effect of P-glycoprotein inhibition at the blood-brain barrier on brain distribution of (R)-[(11) C]verapamil in elderly vs. young subjects","volume":"83","author":"Bauer","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jphs.2021.10.010_bib80","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.clpt.2006.02.004","article-title":"Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[(11)C]verapamil and positron emission tomography","volume":"79","author":"Toornvliet","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jphs.2021.10.010_bib81","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/cpt.2035","article-title":"Abundance of P-glycoprotein and other drug transporters at the human blood-brain barrier in Alzheimer's disease: a quantitative targeted proteomic study","volume":"109","author":"Storelli","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jphs.2021.10.010_bib82","doi-asserted-by":"crossref","first-page":"5489","DOI":"10.1016\/j.bmc.2010.06.057","article-title":"Synthesis and in\u00a0vivo evaluation of [11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor","volume":"18","author":"Bauer","year":"2010","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.jphs.2021.10.010_bib83","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/cpt.362","article-title":"Pilot PET study to assess the functional interplay between ABCB1 and ABCG2 at the human blood-brain barrier","volume":"100","author":"Bauer","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jphs.2021.10.010_bib84","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1124\/dmd.108.024018","volume":"37","author":"Ose","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jphs.2021.10.010_bib85","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1016\/j.xphs.2017.04.040","article-title":"Investigation of the importance of multidrug resistance-associated protein 4 (Mrp4\/Abcc4) in the active efflux of anionic drugs across the blood-brain barrier","volume":"106","author":"Kanamitsu","year":"2017","journal-title":"J\u00a0Pharmacol Sci"},{"key":"10.1016\/j.jphs.2021.10.010_bib86","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1471-4159.2011.07208.x","article-title":"Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors","volume":"117","author":"Uchida","year":"2011","journal-title":"J\u00a0Neurochem"},{"key":"10.1016\/j.jphs.2021.10.010_bib88","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/nbt.2247","article-title":"Derivation of blood-brain barrier endothelial cells from human pluripotent stem cells","volume":"30","author":"Lippmann","year":"2012","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jphs.2021.10.010_bib89","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1124\/jpet.109.162321","article-title":"Kinetic analysis of the cooperation of P-glycoprotein (P-gp\/Abcb1) and breast cancer resistance protein (Bcrp\/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone","volume":"333","author":"Kodaira","year":"2010","journal-title":"J\u00a0Pharmacol Exp Therapeut"},{"key":"10.1016\/j.jphs.2021.10.010_bib90","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0152105","article-title":"Human brain microvascular endothelial cells derived from the BC1 iPS cell line exhibit a blood-brain barrier phenotype","volume":"11","author":"Katt","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jphs.2021.10.010_bib91","doi-asserted-by":"crossref","first-page":"5546","DOI":"10.1021\/acs.molpharmaceut.8b00697","article-title":"Expression and functional characterization of drug transporters in brain microvascular endothelial cells derived from human induced pluripotent stem cells","volume":"15","author":"Kurosawa","year":"2018","journal-title":"Mol Pharm"},{"key":"10.1016\/j.jphs.2021.10.010_bib92","doi-asserted-by":"crossref","first-page":"642812","DOI":"10.3389\/fphys.2021.642812","article-title":"Human induced pluripotent stem cell-derived brain endothelial cells: current controversies","volume":"12","author":"Lu","year":"2021","journal-title":"Front Physiol"},{"key":"10.1016\/j.jphs.2021.10.010_bib93","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0006-8993(01)03337-6","article-title":"A\u00a0co-culture-based model of human blood-brain barrier: application to active transport of indinavir and in\u00a0vivo-in\u00a0vitro correlation","volume":"927","author":"Megard","year":"2002","journal-title":"Brain Res"},{"key":"10.1016\/j.jphs.2021.10.010_bib94","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1124\/dmd.110.032649","article-title":"Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in\u00a0vitro clearance and permeability data","volume":"38","author":"Gertz","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jphs.2021.10.010_bib95","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s10571-007-9195-4","article-title":"Pericytes from brain microvessels strengthen the barrier integrity in primary cultures of rat brain endothelial cells","volume":"27","author":"Nakagawa","year":"2007","journal-title":"Cell Mol Neurobiol"},{"key":"10.1016\/j.jphs.2021.10.010_bib96","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1124\/dmd.120.000115","article-title":"Functional investigation of solute carrier family 35, member F2, in three cellular models of the primate blood-brain barrier","volume":"49","author":"Mochizuki","year":"2021","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jphs.2021.10.010_bib97","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1002\/jps.22487","article-title":"Quantitative membrane protein expression at the blood-brain barrier of adult and younger cynomolgus monkeys","volume":"100","author":"Ito","year":"2011","journal-title":"J\u00a0Pharmacol Sci"},{"key":"10.1016\/j.jphs.2021.10.010_bib98","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1124\/jpet.114.214536","article-title":"Blood-brain barrier pharmacoproteomics-based reconstruction of the in\u00a0vivo brain distribution of P-glycoprotein substrates in cynomolgus monkeys","volume":"350","author":"Uchida","year":"2014","journal-title":"J\u00a0Pharmacol Exp Therapeut"},{"key":"10.1016\/j.jphs.2021.10.010_bib99","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1021\/acs.molpharmaceut.1c00083","article-title":"Abundance of P-glycoprotein and breast cancer resistance protein measured by targeted proteomics in human epileptogenic brain tissue","volume":"18","author":"Brukner","year":"2021","journal-title":"Mol Pharm"},{"key":"10.1016\/j.jphs.2021.10.010_bib100","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1021\/mp200129p","article-title":"Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels","volume":"8","author":"Shawahna","year":"2011","journal-title":"Mol Pharm"},{"key":"10.1016\/j.jphs.2021.10.010_bib101","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/cpt.1373","article-title":"Interindividual and regional variability in drug transporter abundance at the human blood-brain barrier measured by quantitative targeted proteomics","volume":"106","author":"Billington","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jphs.2021.10.010_bib102","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1365-2125.2011.03972.x","article-title":"Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers","volume":"72","author":"Allred","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jphs.2021.10.010_bib105","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.clpt.2004.03.010","article-title":"Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine","volume":"76","author":"Simonson","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jphs.2021.10.010_bib106","doi-asserted-by":"crossref","first-page":"439","DOI":"10.5414\/CPP40439","article-title":"Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A","volume":"40","author":"Park","year":"2002","journal-title":"Int J Clin Pharmacol Therapeut"},{"key":"10.1016\/j.jphs.2021.10.010_bib107","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1111\/j.1600-6143.2005.01005.x","article-title":"Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus","volume":"5","author":"Lemahieu","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jphs.2021.10.010_bib108","unstructured":"New Drug application of teriflunomide (US FDA)."},{"key":"10.1016\/j.jphs.2021.10.010_bib109","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/FJC.0b013e31817b5b5a","article-title":"Effects of atazanavir\/ritonavir or fosamprenavir\/ritonavir on the pharmacokinetics of rosuvastatin","volume":"51","author":"Busti","year":"2008","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.jphs.2021.10.010_bib110","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s13318-019-00577-5","article-title":"Drug-drug interaction potential of darolutamide: In\u00a0vitro and clinical studies","volume":"44","author":"Zurth","year":"2019","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.jphs.2021.10.010_bib111","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s40261-020-00974-8","article-title":"Evaluation of pharmacokinetic drug interactions of the direct-acting antiviral agents elbasvir and grazoprevir with pitavastatin, rosuvastatin, pravastatin, and atorvastatin in healthy adults","volume":"41","author":"Caro","year":"2021","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.jphs.2021.10.010_bib112","unstructured":"New Drug Application for elbasvir\/grazoprevir (US FDA)."},{"key":"10.1016\/j.jphs.2021.10.010_bib113","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/cts.12809","article-title":"Febuxostat, but not allopurinol, markedly raises the plasma concentrations of the breast cancer resistance protein substrate rosuvastatin","volume":"13","author":"Lehtisalo","year":"2020","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jphs.2021.10.010_bib114","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s40268-015-0120-x","article-title":"Effects of fostamatinib on the pharmacokinetics of oral contraceptive, warfarin, and the statins rosuvastatin and simvastatin: results from phase I clinical studies","volume":"16","author":"Martin","year":"2016","journal-title":"Drugs R"},{"key":"10.1016\/j.jphs.2021.10.010_bib115","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.clpt.2003.12.014","article-title":"The effect of gemfibrozil on the pharmacokinetics of rosuvastatin","volume":"75","author":"Schneck","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jphs.2021.10.010_bib116","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1177\/0091270010366446","article-title":"Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin","volume":"51","author":"Whitfield","year":"2011","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.jphs.2021.10.010_bib117","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S0009-9236(03)00052-3","article-title":"Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance","volume":"73","author":"Kyrklund","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jphs.2021.10.010_bib118","unstructured":"New Drug application for glecaprevir\/pibrentasvir (US FDA)."},{"key":"10.1016\/j.jphs.2021.10.010_bib119","unstructured":"New Drug application for grazoprevir."},{"key":"10.1016\/j.jphs.2021.10.010_bib120","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/cpt.525","article-title":"Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A","volume":"101","author":"Prueksaritanont","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jphs.2021.10.010_bib121","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/clpt.2011.142","article-title":"Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study","volume":"90","author":"Maeda","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jphs.2021.10.010_bib122","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1177\/135965350701200711","article-title":"Pharmacokinetics and pharmacodynamics of combined use of lopinavir\/ritonavir and rosuvastatin in HIV-infected patients","volume":"12","author":"van der Lee","year":"2007","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jphs.2021.10.010_bib123","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jhep.2015.01.026","article-title":"Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir\/ritonavir, ombitasvir, and dasabuvir","volume":"63","author":"Menon","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jphs.2021.10.010_bib124","unstructured":"New Drug application for regorafenib (US FDA)."},{"key":"10.1016\/j.jphs.2021.10.010_bib125","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1124\/dmd.117.075531","article-title":"Comparative evaluation of plasma bile acids, dehydroepiandrosterone sulfate, hexadecanedioate, and tetradecanedioate with coproporphyrins I and III as markers of OATP inhibition in healthy subjects","volume":"45","author":"Shen","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jphs.2021.10.010_bib126","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cca.2009.04.003","article-title":"Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism","volume":"405","author":"He","year":"2009","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.jphs.2021.10.010_bib127","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1007\/s00228-013-1554-0","article-title":"Effect of a single-dose rifampin on the pharmacokinetics of pitavastatin in healthy volunteers","volume":"69","author":"Chen","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jphs.2021.10.010_bib128","unstructured":"New Drug Application for sofosbuvir\/velpatasvir\/voxilaprevir (US FDA)."},{"key":"10.1016\/j.jphs.2021.10.010_bib129","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s40262-015-0334-7","article-title":"Use of multiple probes to assess transporter- and cytochrome P450-mediated drug-drug interaction potential of the pangenotypic HCV NS5A inhibitor velpatasvir","volume":"55","author":"Mogalian","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jphs.2021.10.010_bib130","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.2967\/jnumed.109.063289","article-title":"A\u00a0pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET","volume":"50","author":"Wagner","year":"2009","journal-title":"J\u00a0Nucl Med"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861321001055?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861321001055?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T20:03:15Z","timestamp":1761163395000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347861321001055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":127,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S1347861321001055"],"URL":"https:\/\/doi.org\/10.1016\/j.jphs.2021.10.010","relation":{},"ISSN":["1347-8613"],"issn-type":[{"value":"1347-8613","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quantitative prediction of pharmacokinetic properties of drugs in humans: Recent advance in in\u00a0vitro models to predict the impact of efflux transporters in the small intestine and blood\u2013brain barrier","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jphs.2021.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society.","name":"copyright","label":"Copyright"}]}}